Chronic and acute inflammatory demyelinating polyneuropathy are rare diseases with idiopathic aetiology, which is counted among immunomediated polyneuropathies because an autoimmune cause is suspected.
The disease affects the myelin, whose task is to promote the transmission of the nervous impulse along the nerve, as well as protect the nerves from external stimuli.
When the damage reaches the axon often the lesions become irreversible. Approximately 10% of patients have an acute onset, but the subsequent onset of relapse indicates that the disease has a chronic form that can evolve with relapses or progressive worsening. The main symptoms are represented by peripheral muscle weakness, disturbance of sensitivity, tingling and numbness, lack of balance and tremor. Treatment includes corticosteroids, immunoglobulins and plasmapheresis, with the aim of removing the antibodies involved from the bloodstream.
Molecules to be removed:
Antibodies; plasma globulins; IgG, IgA, IgM; cytokines; inflammation mediators
PEX, DFPP, Cascade Filtration